Press release #Healthcare

New PCR rapid test from Bosch for detection of sexually transmitted pathogens

  • New real-time PCR rapid test for detection of four STI
  • First Vivalytic test in cooperation with development partner BioGX
  • Positive test results available within an hour directly at the point of care
Thomas Berroth

Thomas Berroth


Waiblingen – Bosch Healthcare Solutions has received CE-label for the new Vivalytic MG, MH, UP/UU, developed in partnership with BioGX, a US-based global molecular diagnostics company. The test is now available as part of the Vivalytic analyser test portfolio and can thus be used directly at the point of care. This real-time PCR rapid test can detect four pathogens of sexually transmitted infections (STIs): Mycoplasma genitalium (MG), Mycoplasma hominis (MH), Ureaplasma parvum (UP), and Ureaplasma urealyticum (UU). After taking the sample and starting the analysis, a positive result is available in as little as an hour, making the test particularly suitable for use in direct patient care at doctors’ offices and clinics. Here, it can enable STI differential diagnosis directly at the point of sampling without delays due to transportation or logistics. For example, the test can detect in case of infectious urethritis (non-gonorrheal urethritis, NGU)1, if one of the four pathogens is responsible for the infection. However, rapid diagnosis also helps to counteract the further spread of STI pathogens. The Vivalytic MG, MH, UP/UU test saves a lot of time compared to diagnostics by cultivation of the pathogenic germs. In the case of MH, UP, and UU, cultivation can take one to three days, and up to six months for MG2.

One million new infections per day

More than 30 different pathogens can cause STIs. The WHO estimates that one million people worldwide become infected with sexually transmitted pathogens every day3. Even though in most cases infections are asymptomatic, if not detected they can lead to serious health problems and also to impaired sexual health. The four pathogenic germs that the new test detects also belong to the set of human STI pathogens, even though the two ureaplasmas in particular can often occur as commensals4.

Vivalytic analyser: Simple application at the point of sampling

The advantages of PCR rapid tests carried out using the Bosch Vivalytic analyser are not only faster test results, but also ease of use: Once the sample has been taken using a swab, it is placed in the test cartridge. The cartridge, which contains all the reagents required for the respective test, is then inserted into the Vivalytic analyser for automated evaluation. Operation is simple and medical staff can learn how to use it in no time. The length of time needed for the respective analysis depends on the complexity of the test. In addition to the new MG, MH, UP/UU, the Vivalytic product portfolio includes tests for viral respiratory infections (VRI), tests for SARS-CoV-2 – which can also be carried out as a pooling variant and as a lollipop test – as well as a multiplex test for sexually transmitted infections (STIs).

((Text scope: ca. 3.350 characters, incl. spaces))


1) G. Bonkat et al., EAU guidelines on urological infections; European Association of Urology 2020

2) CDC (Centers for Disease Control and Prevention) Guidelines 2021, Publication: Workowski et al., Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187

3), at: 15.03.2022

4) Waites et al., J Mol Diagn. 2012 Sep;14(5):437-50


YouTube channel Bosch Healthcare Solutions

Der Einsatz des Vivalytic Analysers in der Villa Rosenstein

Bosch Healthcare Solutions GmbH is a wholly owned subsidiary of Robert Bosch GmbH. The subsidiary was established in 2015 with the aim of developing products and services that improve people’s health and quality of life. About 120 associates (state 2019) are currently employed at the company’s headquarters in Waiblingen, Germany. The subsidiary’s solutions draw on the Bosch Group’s core competencies: sensors to collect data, software to evaluate that data, and services based on this data analysis.

More information is available online at

The Bosch Group is a leading global supplier of technology and services. It employs roughly 429,000 associates worldwide (as of December 31, 2023). The company generated sales of 91.6 billion euros in 2023. Its operations are divided into four business sectors: Mobility, Industrial Technology, Consumer Goods, and Energy and Building Technology. With its business activities, the company aims to use technology to help shape universal trends such as automation, electrification, digitalization, connectivity, and an orientation to sustainability. In this context, Bosch’s broad diversification across regions and industries strengthens its innovativeness and robustness. Bosch uses its proven expertise in sensor technology, software, and services to offer customers cross-domain solutions from a single source. It also applies its expertise in connectivity and artificial intelligence in order to develop and manufacture user-friendly, sustainable products. With technology that is “Invented for life,” Bosch wants to help improve quality of life and conserve natural resources. The Bosch Group comprises Robert Bosch GmbH and its roughly 470 subsidiary and regional companies in over 60 countries. Including sales and service partners, Bosch’s global manufacturing, engineering, and sales network covers nearly every country in the world. Bosch’s innovative strength is key to the company’s further development. At 136 locations across the globe, Bosch employs some 90,000 associates in research and development, of which nearly 48,000 are software engineers.

Additional information is available online at,,